Psoriatic Arthritis

November 22, 2022

DISCOVER-2 is a phase 3, randomized, double-blind, multicenter study assessing the safety and efficacy of subcutaneous guselkumab treatment in biologic-naïve patients with active PsA.

November 21, 2022

“The data continue to validate our hypothesis that izokibep offers differentiated efficacy with high potency and small size and reinforces izokibep’s potential to manage the hard-to-treat manifestations of PsA."

November 17, 2022

Nowell emphasized that simple changes, such as targeted walking goals and meditative breathing, are low energy and low cost, yet extremely effective.

November 17, 2022

“There's a real interest and need for wellness programs out there among people living with psoriatic arthritis. This is something that matters to them even more now living with a chronic disease.”

November 16, 2022

Deucravacitinib showed sustained efficacy in the various outcomes in psoriatic arthritis and a unique and consistent safety profile.

November 14, 2022

In this Q&A, Fabian Proft, MD, discussed the findings of his study that evaluated the DAPSA using a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis.

November 13, 2022

ABP 501 is an adalimumab biosimilar that was recently approved the European Medicines Agency.

November 09, 2022

Previous studies have suggested a connection between rheumatic diseases, which often affect women in their reproductive years, and adverse pregnancy outcomes, such as pre-eclampsia.

October 31, 2022

The PRERA trial was the first real-world, non-interventional study to analyze radiographic progression in patients with RA or PsA treated with etanercept.

October 26, 2022

Randomized clinical trials evaluating the effect of bDMARD or tsDMARD treatment in patients with psoriatic arthritis were included in the analysis.